Skip to main content

Table 1 Patient characteristics

From: A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

Characteristic Patients
n (%)
Age, years  
 Median 55
 Range 24–77
Sex  
 Male 10 (50)
 Female 10 (50)
Histology  
 PTCL-NOS 10 (50)
 AITL 9 (45)
 ALCL, ALK negative 1 (5)
Stage at enrolment  
 I–II 1 (5)
 III–IV 19 (95)
Extranodal involvement 10 (50)
International Prognostic Index  
 ≥2 16 (80)
No. of prior regimens  
 Median 2
 Range 1–4
Refractory to most recent therapy 12 (60)
  1. PTCL-NOS peripheral T-cell lymphoma not otherwise specified, AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase